Dobrin Vassilev

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Pascal Vranckx, Marco Valgimigli, Peter Jüni et al. · The Lancet · 2018 · 785 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16

Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry

Pasquale Paolisso, Luca Bergamaschi, Gaetano Santulli et al. · Cardiovascular Diabetology · 2022 · 208 citations · Full text

Medicine, Cardiology, Pharmacology +17

Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry

Pasquale Paolisso, Luca Bergamaschi, Felice Gragnano et al. · Pharmacological Research · 2022 · 146 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study

Arturo Cesaro, Felice Gragnano, Pasquale Paolisso et al. · Frontiers in Cardiovascular Medicine · 2022 · 88 citations · Full text

Medicine, Cardiology, Pharmacology +17

Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry

Pasquale Paolisso, Luca Bergamaschi, Arturo Cesaro et al. · Diabetes Research and Clinical Practice · 2023 · 79 citations · Full text

Medicine, Cardiology, Pharmacology +17